Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Issued (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Shares Issued data on record, last reported at $319000.0 in Q3 2025.

  • For Q3 2025, Shares Issued rose 245.66% year-over-year to $319000.0; the TTM value through Dec 2025 reached $319000.0, up 39.3%, while the annual FY2025 figure was $319000.0, 39.3% up from the prior year.
  • Shares Issued reached $319000.0 in Q3 2025 per LCTX's latest filing, up from $229000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $33.1 million in Q2 2021 and bottomed at -$6.5 million in Q4 2023.
  • Average Shares Issued over 5 years is $3.0 million, with a median of $180500.0 recorded in 2024.
  • Peak YoY movement for Shares Issued: skyrocketed 985.41% in 2023, then tumbled 103.35% in 2024.
  • A 5-year view of Shares Issued shows it stood at $33.1 million in 2021, then plummeted by 98.18% to $603000.0 in 2022, then crashed by 1184.08% to -$6.5 million in 2023, then surged by 103.5% to $229000.0 in 2024, then soared by 39.3% to $319000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $319000.0 in Q3 2025, $229000.0 in Q4 2024, and -$219000.0 in Q3 2024.